Eli Lilly disclosed a $3.5 billion manufacturing investment to produce its next-generation obesity injectables, including retatrutide, at a new Lehigh Valley facility. The plant will house both drug production and device manufacturing for injectable therapeutics, addressing supply-chain capacity constraints as global demand for GLP‑based and next-gen peptide weight‑loss medicines surges. Lilly framed the factory as a strategic move to secure commercial supply for its expanding obesity portfolio and to support faster patient access for high-volume launch medicines.